OptimizeRx Corporation reported significant financial improvements in its latest 10-Q filing for the third quarter of 2025, showcasing a net revenue increase of 22% to $26.1 million compared to $21.3 million in the same period last year. For the nine months ending September 30, 2025, revenue rose by 29% to $77.2 million from $59.8 million in 2024. The company attributed this growth primarily to increased sales from its Direct-to-Consumer (DTC) and Dynamic Audience Activation Platform (DAAP) offerings. Gross profit for the third quarter was $17.5 million, yielding a gross margin of 67.2%, up from 63.1% in the prior year.
The company also reported a notable turnaround in profitability, achieving a net income of $779,000 for the third quarter, a stark contrast to the net loss of $9.1 million recorded in the same quarter of 2024. For the nine-month period, net income was $112,000, compared to a loss of $20 million in the previous year. This improvement was supported by a reduction in operating expenses, which fell by approximately 30% to $15.5 million for the third quarter, down from $22 million in 2024. The decrease in expenses was largely due to the absence of goodwill impairment charges that had impacted the previous year’s results.
In terms of operational metrics, OptimizeRx reported a current ratio of approximately 3.0 to 1, indicating a solid liquidity position with total current assets of $56.3 million against current liabilities of $18.5 million. The company’s cash and cash equivalents increased to $19.5 million from $13.4 million at the end of 2024. The total employee headcount remained stable, reflecting the company's focus on efficiency and productivity, as evidenced by a year-over-year increase in revenue per average full-time employee, which rose to $820 from $732.
Strategically, OptimizeRx has been expanding its service offerings and customer base, focusing on enterprise-level engagements and innovative solutions like its patented Micro-Neighborhood Targeting. The company has approximately 100 pharmaceutical clients, with its top five customers accounting for 49% of total revenue. The company is also actively managing its debt, having entered a $40 million term loan agreement in October 2023 to finance the acquisition of Medicx Health, with an outstanding balance of approximately $28.8 million as of September 30, 2025.
Looking ahead, OptimizeRx remains optimistic about its growth trajectory, driven by its strategic initiatives and the anticipated benefits from its expanded product offerings. The company expects to continue leveraging its technology platform to enhance customer engagement and drive revenue growth, while also maintaining a focus on improving margins through a shift towards subscription-based models for its data services. However, the company acknowledges potential risks, including economic uncertainties and customer concentration, which could impact future performance.
About OptimizeRx Corp
OptimizeRx Corporation is a healthcare technology company specializing in digital marketing solutions for the life sciences industry. It offers AI-driven audience targeting, omnichannel engagement, and patient and provider communication platforms. Serving pharmaceutical manufacturers and healthcare providers, it enhances brand visibility, patient access, and treatment support through proprietary data, privacy-safe targeting, and integrated digital channels. Its business model focuses on innovative, scalable solutions to improve healthcare marketing and patient outcomes.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.